In treating elderly non-Hodgkin’s lymphoma (NHL) patients, it is particularly important to use drugs that have a low incidence
of adverse events and high efficacy. In this multicenter study, THP (pirarubicin)-COP (cyclophosphamide, vincristine, and
prednisolone) was compared to two thirds dosage of full CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)
regimen with regard to both adverse events and efficacy. For a third group, etoposide (E) was added to the THP-COP regimen
(THP-COPE) in order to achieve high dose-intensity. Subjects were 486 previously untreated patients, aged 65 or older (range,
65–92 years; median, 74 years), with NHL. Subjects were randomly assigned to receive THP-COP, two thirds CHOP, or THP-COPE.
Four hundred and forty-three patients were assessed for response and followed for 8 years after the last subject registered.
The complete remission rates for the THP-COP, CHOP, and THP-COPE groups were 42.5%, 41.4%, and 48.0%, respectively. There
was no difference in overall survival or progression-free survival among these 3 groups. In aggressive lymphoma, there was
also no difference in complete response (CR) rate (45.3% in THP-COP, 44.9% in CHOP, 48.0% in THP-COPE), overall survival,
and progression-free survival among these groups. The 5- and 8-year survival rates for all patients were 29.4% and 18.7%,
respectively. The 5- and 8-year survival rates for patients with aggressive lymphoma were 27.4% and 17.4%, respectively. Although
long-term survival for patients with aggressive lymphoma on our regimens was not worse compared to previous reports, the CR
rate was lower. Because severe adverse events were not observed, higher dose chemotherapy may be directed to achieve better
CR rates. In patients with T-cell-type lymphoma, the CR rate was greater after treatment with THP-COP (51.4%) or THP-COPE
(57.7%) compared to treatment with CHOP (19.4%). Pirarubicin may be more useful for T-cell lymphoma than doxorubicin. Because
adverse cardiac events were reported only in CHOP, adverse cardiac events might be low in the THP group.
Key words Non-Hodgkin’s lymphoma - Elderly - Randomized trial - Pirarubicin - Doxorubicin